Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lisa Becker has been appointed as Vice President, Regulatory Affairs, Global Angina Therapies
  • Sarah Gallagher has been appointed as Vice President, Clinical Affairs
  • Ms. Becker has more than 20 years of experience in medical device regulatory affairs
  • Ms. Becker holds a Bachelor of Science and a Masters of Science
  • Ms. Gallagher brings 20 years of medical device clinical research experience to the Neovasc team
  • Ms. Gallagher holds a Bachelor of Applied Arts in Exercise Science, a Bachelor of Arts in Psychology and a Master of Science in Technology Management
  • Neovasc is a specialty medical device company
  • Neovasc Inc. (NVCN) opened trading at C$1.10 per share

Neovasc (NVCN) has appointed Lisa Becker as Vice President, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as Vice President, Clinical Affairs.

“Neovasc’s Regulatory and Clinical teams will be well strengthened with the additions of Lisa and Sarah, who bring tremendous experience in regulatory and clinical affairs to the overall Neovasc team,” said Fred Colen, President and Chief Executive Officer of Neovasc.

“We look forward to leveraging their industry expertise as we pursue our own development goals in North America and Europe.”

Ms. Becker has more than 20 years of experience in medical device regulatory affairs. She possesses regulatory experience on a global scale, with responsibility for multiple geographies, including US and EU Class III approvals.

Ms. Becker earned a Bachelor of Science in Organizational Behavior with a General Engineering minor from the United States Air Force Academy and a Masters of Science from Chapman University. 

She served nearly ten years on active duty as an officer in the US Air Force. A highlight of Ms. Becker’s career includes the approval of the world’s smallest mechanical heart valve and a duct occluder for premature infants, which was approved in four major geographies within a six-month period.

“I view my regulatory work as a continuation of my service toward improving lives. As a member of the Neovasc team, I will bring my professional passion for driving medical device development through creative and collaborative regulatory approval strategies to the Company’s efforts to expand approval and acceptance of the Reducer device,” said Ms. Becker.

Ms. Gallagher brings 20 years of medical device clinical research experience to the Neovasc team. 

Prior to joining Neovasc, she held leadership roles at Medtronic in Interventional Pain, Neuromodulation, and Cardiac Rhythm Management, as well as St. Jude Medical in Structural Heart. During her tenure, she held roles with increasing responsibility in clinical research and clinical operations, and she has developed and executed both pre-and post-market clinical trials and supported regulatory approvals globally. 

Ms. Gallagher holds a Bachelor of Applied Arts in Exercise Science and a Bachelor of Arts in Psychology from the University of Minnesota, and a Master of Science in Technology Management from the University of St. Thomas.

“I am excited to be joining the Neovasc Clinical Affairs team at this critical point in the Company’s corporate and clinical journey,” said Ms. Gallagher. “I am eager to engage in the ongoing and new studies and data supporting the Reducer and Tiara programs, as we seek to bring these important treatment options to more patients.”

Neovasc also announces the departure of Vicki Bebeau, former Vice President of Clinical and Regulatory affairs who is assisting with transitioning activities to Sarah and Lisa until August 30, 2021.

Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina and Tiara, for the transcatheter treatment of mitral valve disease.

Neovasc Inc. (NVCN) opened trading at C$1.10 per share.

More From The Market Herald
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.
Nanalysis (TSXV:NSCI) - Founder & CEO, Sean Krakiwsky.

" Nanalysis (TSXV:NSCI) signs $160M security contract

Nanalysis Scientific (NSCI) has signed a six-year $160 million contract with Canadian Air Transportation Security Authority (CATSA).